Sun Pharma to acquire Nasdaq-listed Checkpoint Therapeutics for $355 million; shares edge higher

Sun Pharmaceutical Industries Ltd. has announced the acquisition of Nasdaq-listed Checkpoint Therapeutics, Inc., an immunotherapy and targeted oncology company, in a $355 million cash deal. The acquisition will bolster Sun Pharma’s onco-dermatology portfolio, adding Checkpoint’s recently FDA-approved cancer drug, UNLOXCYT (cosibelimab-ipdl), to its pipeline. The deal, expected to close in the second quarter of the…

Read More

Cancer was fastest-growing ailment in 2024: Medi Assist report

Cancer was the fastest-growing ailment in India in 2024, while respiratory illnesses saw the highest increase in the average cost of treatment, a report released by health benefits administrator Medi Assist said on Thursday. Cancer incidence rates—the percentage of claims with respect to overall people insured—grew 10-12% year-on-year in 2024, according to the report. Incidences…

Read More
Back To Top